Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-14

Clinical Trial Update: A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis [Phase 2]

View source ↗

Summary

A phase 2 trial tested whether BI 655130 (spesolimab) can prevent flare-ups in generalized pustular psoriasis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spesolimab (BI 655130) (spesolimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Generalized Pustular Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2023-12-14